ROCKET PHARMACEUTICALS, INC.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company focused on developing, manufacturing, and commercializing genetic therapies for rare and often fatal diseases with high unmet medical need. The company operates through a multi-platform approach utilizing… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ROCKET PHARMACEUTICALS, INC. does
In the company’s own words
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company focused on developing, manufacturing, and commercializing genetic therapies for rare and often fatal diseases with high unmet medical need. The company operates through a multi-platform approach utilizing adeno-associated virus (AAV) and lentiviral (LV) vector technologies to create gene therapy product candidates designed to correct underlying genetic causes of complex inherited cardiomyopathies and related disorders.
The company's pipeline is organized around two primary therapeutic areas: cardiovascular programs and hematology programs. In cardiovascular development, Rocket is advancing RP-A501 for Danon disease, RP-A601 for plakophilin-2 arrhythmogenic cardiomyopathy, and RP-A701 for BAG3 dilated cardiomyopathy. In hematology, the company is developing KRESLADI™ (marnetegragene autotemcel) for leukocyte adhesion deficiency-I, which received a Complete Response Letter from the FDA and was resubmitted for review with a PDUFA date of March 28, 2026. The company also maintains programs in Fanconi anemia and pyruvate kinase deficiency, though these have been de-prioritized as part of a strategic restructuring announced in July 2025.
Rocket operates approximately 100,000 square feet of in-house AAV current good manufacturing practice (cGMP) manufacturing facilities in Cranbury, New Jersey, enabling end-to-end control of clinical production, process development, and scale-up for potential commercialization. The company's leadership team brings extensive experience in cell and gene therapies and rare diseases, with a track record of over 20 successful U.S. and international drug approvals and launches.
In July 2025, Rocket announced a strategic corporate reorganization and pipeline prioritization designed to maximize near-term value and extend operational runway. This initiative included a reduction in workforce of approximately 30 percent and is expected to reduce 12-month operating expenses by approximately 25 percent. The company's strategy emphasizes a first-and-best-in-class approach, targeting monogenic diseases with differentiated therapies offering potential for superior clinical profiles and sustainable value creation. More information is available at www.rocketpharma.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1281895
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ROCKET PHARMACEUTICALS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ROCKET PHARMACEUTICALS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ROCKET PHARMACEUTICALS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ROCKET PHARMACEUTICALS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ROCKET PHARMACEUTICALS, INC.'s last four quarterly filings that the numbers alone won't show?”